HC Wainwright Estimates Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Cytokinetics in a research report issued to clients and investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($1.57) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $136.00 price objective on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.61) EPS and Q4 2026 earnings at ($1.89) EPS.

Several other equities analysts also recently issued reports on CYTK. Barclays assumed coverage on Cytokinetics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $87.00 price objective for the company. UBS Group restated a “neutral” rating and issued a $61.00 price target on shares of Cytokinetics in a research report on Monday, December 1st. Citizens Jmp upped their price objective on shares of Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a research note on Wednesday. Royal Bank Of Canada raised their target price on Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Finally, Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. Seventeen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $88.83.

Cytokinetics Stock Performance

CYTK stock opened at $62.22 on Thursday. The stock has a market capitalization of $7.61 billion, a price-to-earnings ratio of -9.53 and a beta of 0.54. The stock’s fifty day moving average is $64.20 and its two-hundred day moving average is $58.58. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. The company’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned ($1.26) earnings per share.

Insider Buying and Selling

In related news, EVP Andrew Callos sold 15,000 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00. Following the transaction, the executive vice president directly owned 50,440 shares in the company, valued at $3,123,749.20. The trade was a 22.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Fady Ibraham Malik sold 2,200 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $61.24, for a total value of $134,728.00. Following the completion of the transaction, the executive vice president owned 138,552 shares of the company’s stock, valued at $8,484,924.48. The trade was a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 151,385 shares of company stock valued at $9,817,158 over the last three months. 2.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Millennium Management LLC raised its holdings in shares of Cytokinetics by 361.9% in the first quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock valued at $11,571,000 after buying an additional 225,576 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its holdings in Cytokinetics by 50.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 61,783 shares of the biopharmaceutical company’s stock worth $2,041,000 after buying an additional 20,751 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Cytokinetics by 21.2% during the second quarter. Envestnet Asset Management Inc. now owns 29,467 shares of the biopharmaceutical company’s stock valued at $974,000 after purchasing an additional 5,146 shares during the period. Teacher Retirement System of Texas grew its stake in Cytokinetics by 1.1% in the second quarter. Teacher Retirement System of Texas now owns 30,514 shares of the biopharmaceutical company’s stock valued at $1,008,000 after acquiring an additional 341 shares during the period. Finally, Peregrine Capital Management LLC raised its holdings in Cytokinetics by 1.8% during the 2nd quarter. Peregrine Capital Management LLC now owns 158,528 shares of the biopharmaceutical company’s stock worth $5,238,000 after buying an additional 2,791 shares during the period.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.